Anagenex, Inc.

Drug discovery platform that combines machine learning (ML) with DNA Encoded Libraries (DELs)

Founded in late 2019 by Lux Ventures and Nicolas Tilmans to focus on difficult targets of therapeutic value based on a novel ML platform. The platform enables rapid analysis of 100-1000x more compounds compared to traditional approaches by combining machine learning (ML) with DNA Encoded Libraries (DELs). In contrast to legacy approaches, ML oriented DELs generate enormous amounts of useful data enabling identification of better compounds faster than competing solutions.